Comins' reagent

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: Comins' reagent
• 英文别名: N-(4-chlorophenyl)-1,1,1-trifluoro-N-((trifluoromethyl)sulfonyl)methanesulfonamide；4-Chloro-N,N-bis(trifluoromethanesulfonyl)aniline；N-(4-chlorophenyl)-1,1,1-trifluoro-N-(trifluoromethylsulfonyl)methanesulfonamide
• 化学式: C₈H₄ClF₆NO₄S₂
• 分子量: 391.699
• InChiKey: XXVDFSLIEDFCCG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  22
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  88.3
• 氢给体数：
  0
• 氢受体数：
  11

反应信息

• 作为反应物：
  描述：

  Comins' reagent 、 N-叔丁氧羰基-去甲托品酮 在 lithium diisopropyl amide 作用下， 以 四氢呋喃 为溶剂， 反应 1.5h， 生成 (1R,5S)-3-(三氟甲基磺酰氧基)-8-氮杂双环[3.2.1]-2-辛烯-8-羧酸叔丁酯
  参考文献：
  名称：

  [EN] PYRIMIDOPYRAN COMPOUND
  [FR] COMPOSÉ PYRIMIDOPYRANE
  [ZH] 嘧啶并吡喃类化合物

  摘要：

  涉及一类嘧啶并吡喃类化合物，具体公开了式(III)所示化合物及其药学上可接受的盐。

  公开号：

  WO2022161443A1
• 作为产物：
  描述：

  p-chlorobenzenediazonium tetrafluoroborate 、 1-丁基-3-甲基咪唑二(三氟甲基磺酰)酰亚胺 反应 240.0h， 生成 Comins' reagent 、 N-[(4-chlorophenoxy)-oxo-(trifluoromethyl)-lambda6-sulfanylidene]-1,1,1-trifluoromethanesulfonamide 、 1-氯-4-氟苯
  参考文献：
  名称：

  N-(Trifluoromethylsulfonyl)aryloxytrifluoromethylsulfoximines [ArO−SO(CF₃)NTf] and N-Aryltriflimides Ar−N(Tf)₂ by Thermal and Photolytic Dediazoniation of [ArN₂][BF₄] in [BMIM][Tf₂N] Ionic Liquid:  Exploiting the Ambident Nucleophilic Character of a “Nonnucleophilic” Anion

  摘要：

  Arenediazonium tetrafluoroborate salts undergo metathesis on immobilization in 1-butyl-3-methylimidazolium bis(trifluoromethanesulfonato)amide [BMIM][Tf2N]. The "noncoordinating", "nonnucleophilic" [Tf2N] anion acts as an ambident nucleophile toward the aryl cations, formed via thermal dediazoniation, to give predominantly the oxy anion quenching products [ArO-SO(CF3)NTf], with minimal formation of ArN(Tf)(2), irrespective of the nature of the substituent(s) on the ArN2+. Strong preference for the formation of oxygen trapping products did not change under photolytic conditions, where dediazoniation occurs at room temperature. A minimal amount of the Schiemann product ArF is also formed in both thermal and photolytic dediazoniation, depending on the substituent(s). Progress of dediazoniation in the IL (both thermal and photolytic) and the evolution of the products were directly monitored by H-1 and F-19 NMR. According to DFT (Density Functional Theory) calculations, PhN(Tf)(2) is more stable than PhO-SO(CF3)NTf by 15-17 kcal/mol, depending on the basis set. Inclusion of solvation effects (PCM, with acetone and with CH2ClCH2Cl as solvent) did not change this preference. The [ArN2][BF4] dediazoniation in [BMIM][Tf2N] resulted in synthesis and characterization of a series of hitherto unknown [ArO-SO(CF3)NTf] compounds. The X-ray structure of MesO-SO(CF3)NTf (Mes = mesityl) is reported. On the basis of extraction studies, suitable solvent systems have been identified that remove the products without dissolving [BMIM][NTf2], thus overcoming product recovery difficulties typically associated with the use of this IL.

  DOI：

  10.1021/jo0708801

文献信息

• Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment
  申请人：Raghavan Subharekha

  公开号：US20090062269A1

  公开（公告）日：2009-03-05

  The present invention encompasses compounds of Formula I: as well as pharmaceutically acceptable salts and hydrates thereof, that are useful for treating atherosclerosis, dyslipidemias and the like. Pharmaceutical compositions and methods of use are also included.

  本发明涵盖了Formula I的化合物，以及其药用盐和水合物，可用于治疗动脉粥样硬化、血脂异常等疾病。药物组合物和使用方法也包括在内。
• [EN] ISOINDOLINONE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE<br/>[FR] INHIBITEURS D'ISOINDOLINONE DE PHOSPHATIDYLINOSITOL 3-KINASE
  申请人：VERTEX PHARMA

  公开号：WO2011087776A1

  公开（公告）日：2011-07-21

  The present invention relates to compounds useful as inhibitors of PI3K, particularly of PI3Kγ. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.

  本发明涉及作为PI3K抑制剂的化合物，特别是PI3Kγ的抑制剂。该发明还提供了包含上述化合物的药用合适组合物，并提供了使用这些组合物治疗各种疾病、状况或障碍的方法。
• THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN
  申请人：Kyle Donald J.

  公开号：US20110152324A1

  公开（公告）日：2011-06-23

  A compound of formula: wherein Ar 1 , Ar 2 , V, X, R 3 , R 4 , and m are as disclosed herein or a pharmaceutically acceptable salt thereof (a “Cyclo(hetero)alkenyl Compound”); compositions comprising an effective amount of a Cyclo(hetero)alkenyl Compound; and methods for treating or preventing, e.g., pain, UI, an ulcer, IBD, or IBS in an animal, comprising administering to an animal in need thereof an effective amount of a Cyclo(hetero)alkenyl Compound are disclosed herein.

  本文披露了一种化合物，其化学式为：其中Ar1，Ar2，V，X，R3，R4和m如本文所述，或其药物可接受的盐（“环（杂）烯基化合物”）；包含有效量的环（杂）烯基化合物的组合物；以及治疗或预防动物的疼痛、尿失禁、溃疡、炎症性肠病或肠易激综合征等疾病的方法，包括向需要治疗的动物投与有效量的环（杂）烯基化合物。
• ISOINDOLINONE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE
  申请人：Aronov Alex

  公开号：US20120040950A1

  公开（公告）日：2012-02-16

  The present invention relates to compounds useful as inhibitors of PI3K, particularly of PI3Kγ. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.

  本发明涉及用作PI3K抑制剂的化合物，特别是PI3Kγ的抑制剂。本发明还提供包含该化合物的药学上可接受的组合物，并提供使用该组合物治疗各种疾病、病况或疾病的方法。
• ABC → ABCE/D Based Approaches to the Pentacyclic Ring System of the Vinca Alkaloids Using Intramolecular Hetero-[2+2]cycloaddition and Gold(I)-Catalyzed 6-endo-dig Cyclisation Protocols
  作者：Martin G. Banwell、Lorenzo V. White、Anthony C. Willis

  DOI：10.3987/com-14-s(k)19

  日期：——

  The angularly substituted tetrahydrocarbazole 13, which is readily obtained from cyclohexane-1,4-dione monoethylene ketal (6) using Fischer indole chemistry, has been converted into the isothiocyanate 16. Photolysis of this last compound affords, via an intramolecular hetero[2+2]cycloaddition reaction, the pentacyclic beta-thiolactam 17 that incorporates the ABCE ring substructure of natural products 1-3. Attempts to effect a two-carbon homologation of the four-membered ring within compound 17, and thereby establish the D-ring, failed. The azide 20, also obtained from compound 13, forms the cyclic imine 21 on thermolysis in refluxing toluene and the readily derived enamide 23 engages in a Au(I)-catalysed 6-endo-dig cyclisation reaction to give compound 24 embodying the ABCDE ring system of the title alkaloids.